CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.

Clinical trial NCT04037566 · UNKNOWN

Trial details

NCT number: NCT04037566
Sponsor: Xijing Hospital
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Leukemia Lymphocytic Acute (ALL) in Relapse Leukemia Lymphocytic Acute (All) Refractory Lymphoma, B-Cell CD19 Positive

Start date: 2019-08-01
Primary completion: 2021-08-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.